New Privacy Rules in Economic Stimulus Law Will They Restrict Certain Pharmaceutical Marketing Practices?
Beefed-up patient privacy protections in the recently enacted economicstimulus package are expected to place significant new restrictions onhow some players in the pharmaceutical supply chain, including chaindrugstores and PBMs, gather and distribute prescribing information topharmaceutical firms for what critics claim is the purpose of marketingdrugs.
This article reviews the medical privacy restrictionsincluded in the American Recovery and Reinvestment Act, which PresidentObama signed into law on Feb. 17, 2009, and discusses the impact theserestrictions might have on pharmaceutical marketing.
Topic headings include:
- Limits Placed on HIPAA Exclusions
- Could Curtail Marketing
- Critics Warn That Rx Data Are Still Accessible
- Ensuring That Privacy Doesn’t Hamper HIT
Read this article now. It’s FREE…
Issue: Vol. 8, No. 3: March 2009
Word Count: 1333
- Direct-to-Consumer (DTC) Advertising & Marketing
- Compliance Marketing & Education
- Regulatory Compliance